An Era of Therapeutic Evolution and Revolution: Insights into Studies on Dupilumab, Tralokinumab, Lebrikizumab, Nemolizumab, Eblasakimab, and OX40/OX40L Agents (Rocatinlimab and Amlitelimab) in Moderate-to-Severe Atopic Dermatitis
IntechOpen eBooks